Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly by Beugeling, Max et al.
  
 University of Groningen
Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins
intended for pregnant women and the elderly
Beugeling, Max; De Zee, Jildou; Woerdenbag, Herman J.; Frijlink, Henderik W.; Wilschut, Jan
C.; Hinrichs, Wouter L. J.
Published in:
Expert review of vaccines
DOI:
10.1080/14760584.2019.1657013
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Beugeling, M., De Zee, J., Woerdenbag, H. J., Frijlink, H. W., Wilschut, J. C., & Hinrichs, W. L. J. (2019).
Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for
pregnant women and the elderly. Expert review of vaccines, 18(9), 935-950.
https://doi.org/10.1080/14760584.2019.1657013
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-01-2020
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ierv20
Expert Review of Vaccines
ISSN: 1476-0584 (Print) 1744-8395 (Online) Journal homepage: https://www.tandfonline.com/loi/ierv20
Respiratory syncytial virus subunit vaccines based
on the viral envelope glycoproteins intended for
pregnant women and the elderly
Max Beugeling, Jildou De Zee, Herman J. Woerdenbag, Henderik W. Frijlink,
Jan C. Wilschut & Wouter L.J. Hinrichs
To cite this article: Max Beugeling, Jildou De Zee, Herman J. Woerdenbag, Henderik W. Frijlink,
Jan C. Wilschut & Wouter L.J. Hinrichs (2019) Respiratory syncytial virus subunit vaccines based
on the viral envelope glycoproteins intended for pregnant women and the elderly, Expert Review of
Vaccines, 18:9, 935-950, DOI: 10.1080/14760584.2019.1657013
To link to this article:  https://doi.org/10.1080/14760584.2019.1657013
© 2019 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 25 Aug 2019.
Submit your article to this journal 
Article views: 723
View related articles 
View Crossmark data
REVIEW
Respiratory syncytial virus subunit vaccines based on the viral envelope
glycoproteins intended for pregnant women and the elderly
Max Beugelinga, Jildou De Zeea, Herman J. Woerdenbaga, Henderik W. Frijlinka, Jan C. Wilschutb and
Wouter L.J. Hinrichsa
aDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands; bDepartment of Medical
Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
ABSTRACT
Introduction: Respiratory syncytial virus (RSV) causes high morbidity and mortality rates among infants,
young children, and the elderly worldwide. Unfortunately, a safe and effective vaccine is still unavail-
able. In 1966, a formalin-inactivated RSV vaccine failed and resulted in the death of two young children.
This failure shifted research toward the development of subunit-based vaccines for pregnant women
(to passively vaccinate infants) and the elderly. Among these subunit-based vaccines, the viral envelope
glycoproteins show great potential as antigens.
Areas covered: In this review, progress in the development of safe and effective subunit RSV vaccines
based on the viral envelope glycoproteins and intended for pregnant women and the elderly, are
reviewed and discussed. Studies published in the period 2012–2018 were included.
Expert opinion: Researchers are close to bringing safe and effective subunit-based RSV vaccines to the
market using the viral envelope glycoproteins as antigens. However, it remains a major challenge to elicit
protective immunity, with a formulation that has sufficient (storage) stability. These issues may be
overcome by using the RSV fusion protein in its pre-fusion conformation, and by formulating this protein
as a dry powder. It may further be convenient to administer this powder via the pulmonary route.
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Human respiratory syncytial virus (RSV) is the most important
cause of severe lower respiratory tract infections among
infants and young children worldwide [1–4]. It has been esti-
mated that, in 2015, globally 33.1 million children under
5 years of age suffered from RSV-associated acute lower
respiratory infection (RSV-ALRI). Of these children, 3.2 million
required hospitalization. In that same year, approximately
118,200 children deceased from RSV-ALRI [5]. RSV is also an
important cause of severe morbidity and mortality among the
elderly (≥65 years) [6].
The virus is transmitted via aerosols and through contact
with contaminated surfaces [7]. After an initial RSV infection
there is usually no long-lasting immunological memory
against RSV. As a result, reinfections occur frequently [8]. Hall
et al. [9] demonstrated this by challenging adults with RSV
after a natural infection. Almost 50% of them were reinfected
within 2 months. In the study period of 26 months, 73% were
infected at least twice, and 47% were even infected three
times or more. However, two subsequent infections within
a short period of time tended to improve the immunological
memory. Higher serum antibody levels before RSV challenge
correlated with protection from infection, but the rate of
reinfection was still 25% among subjects with the highest
antibody titers.
Despite the significant global health burden and over
50 years of research, no vaccine against RSV is available on
the market yet. Currently, palivizumab is the only approved
therapeutic agent against RSV infection [10]. This monoclonal
antibody binds to the fusion (F) protein of the virus [11,12].
Palivizumab is only used prophylactically with infants who are
at high risk for hospitalization due to RSV infection and it
needs to be administered monthly for a longer period [13].
The high costs of multiple dosing with palivizumab restricts its
use, especially in low- and middle-income countries [12].
Moreover, repeated injections are a burden for the patient.
Ribavirin, a nucleoside analog, is also used for the treat-
ment of RSV infection in high-risk patients [14]. Usually, it is
administered pulmonary in an aerosolized form. Treatment
with ribavirin has limitations: it is very costly, difficult to
administer, and has limited clinical efficacy [12,15].
In view of the current drawbacks in RSV prophylaxis and
therapy, the development of a safe and effective RSV vaccine
is urgently needed. In a trial in 1966, formalin-inactivated virus
(FI-RSV) was used as a vaccine. This vaccine candidate was
investigated in infants and young children and yielded mod-
erate serum antibody levels, but appeared to be unable to
protect against RSV infection [16,17]. By contrast, vaccinated
infants even developed more serious lower respiratory tract
disease upon natural RSV infection than did infants who had
not received the FI-RSV vaccine. This phenomenon is known as
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vaccine-enhanced respiratory disease [18]. Two of the thirty-
one vaccinated children died during the trial [17]. The failure
of the FI-RSV vaccine hampered research toward new RSV
vaccines for many years after that study.
In recent years, however, extensive research was done on the
development of an RSV vaccine and researchers are getting closer
to bringing a safe and effective vaccine to the market. In
December 2015, 60 different RSV vaccine candidates were
in preclinical or clinical development [12]. Many different
approaches have been followed in the development of an effec-
tive RSV vaccine (e.g. live-attenuated, whole inactivated, subunit-
based vaccines), as different target groups for RSV vaccination
require different vaccine formulations [19–21]. The different target
groups for RSV vaccination are: infants (≤6 months of age), young
children (6–24 months of age), pregnant women (to passively
vaccinate neonates), and the elderly (≥65 years of age) [19–21].
The target group with the highest priority is infants [20]. However,
since the failure of the FI-RSV vaccine, vaccinating this specific
target group encounters resistance and remains elusive. On the
other hand, a growing interest is seen for vaccination of pregnant
women. The goal of vaccinating this target group is to induce high
titers of neutralizing antibodies which are passively transferred to
the fetus and thus may protect infants during the crucial first
months of life [19,20,22]. According to Anderson et al. [20], sub-
unit-based vaccines are considered for this purpose, as live RSV
vaccines have not been sufficiently immunogenic in adults.
For the same reason, subunit-based vaccines are also con-
sidered for another important target group, being the elderly
[20]. A major challenge of this target group is immunosenes-
cence, which may result in an unbalanced immune response
[19]. Therefore, it is likely that a subunit-based vaccine for the
elderly will have to be co-formulated with adjuvants to recall
pre-existing immunity and to elicit a balanced immune
response [21]. For both target groups, pregnant women and
the elderly, vaccine-enhanced respiratory disease is consid-
ered not to be a concern, since these target groups have
been infected with a live virus multiple times [20,23]. In con-
clusion, subunit-based RSV vaccines show great promise for
different target groups.
Several antigens can potentially be used for the develop-
ment of subunit-based RSV vaccines. However, from recent
literature it is clear that the F protein is considered as the
most promising antigen. This is also supported by the fact that
virus-neutralizing (VN) antibodies are targeted at this glyco-
protein upon RSV infection [24].
This review focuses on the viral envelope glycoproteins,
and in particular the F protein (in both the pre-fusion (pre-F)
and the post-fusion (post-F) conformation), as antigens. The
structure of RSV and the viral envelope glycoproteins are first
discussed, after which recent advances in the development of
subunit-based RSV vaccines, using the viral envelope glyco-
proteins as antigens, are reviewed. For the latter part, only
studies published in the period 2012–2018 were included. The
review was conducted using PubMed and the following search
terms were used: respiratory syncytial virus, vaccine, attach-
ment protein, fusion protein, virosomes, structure, hospitaliza-
tion, and treatment.
2. The structure of RSV
RSV is an enveloped, negative-sense, single-stranded RNA virus,
which belongs to the genus Orthopneumovirus of the family
Pneumoviridae [25,26]. This family also includes human metap-
neumovirus, which after RSV represents the second most com-
mon cause of lower respiratory tract infections among young
children [27]. Two different subtypes of RSV can be distin-
guished, namely RSV A and RSV B [28]. The structure of the
virus is shown in Figure 1 [29]. The virus consists of a lipid
envelope containing a nucleocapsid, and is pleomorphic with
different sizes of spherical particles and filamentous particles
[30]. The RSV genome contains approximately 15,200 nucleo-
tides, encoding 11 different proteins [31]. The transmembrane
surface glycoproteins protrude from the outside of the lipid
bilayer and are 11–20 nm in size [29]. The RSV genome, pro-
teins, and their functions are shown in Figure 2 [29].
NS1 and NS2 are non-structural proteins, which are not
packaged inside RSV virions, but only detected in RSV-
infected cells [32]. They mainly inhibit the production of inter-
feron (IFN), specifically IFN-α and IFN-β, by the host cell [33]. The
nucleocapsid (N) protein offers protection for the viral RNA.
N and phosphoprotein (P) are essential for transcriptional activ-
ity [29]. The matrix (M) protein is important for virus assembly,
as it connects the nucleocapsid with the envelope proteins
[29,34]. The M2 gene encodes two proteins, M2-1 and M2-2.
M2-1 functions as an elongation factor in transcription and M2-
2 is involved in regulation of viral RNA transcription and replica-
tion [35,36]. The long gene L encodes the RNA polymerase of
the virus [27,29], which replicates the viral RNA and is also
involved in polyadenylation, capping, and methylation [29,37].
Three different proteins are present on the outer surface of
the virus membrane: the F protein, the G protein, and the
small hydrophobic (SH) protein [24]. The F and G proteins are
the viral envelope glycoproteins, which will be discussed in
more detail in the next section. The SH protein is a small
protein that is found in infected cells and on the membrane
of the virus [24]. The SH protein forms a pentameric ion
channel complex. Its biological function is still unknown [38].
Article highlights
● The highly conserved fusion protein is a promising antigen for the
development of subunit RSV vaccines for pregnant women and the
elderly.
● Subunit-based RSV vaccines using the viral envelope glycoproteins as
antigens elicit high virus-neutralizing antibody titers in animal mod-
els and in human trials.
● Three recent clinical studies with RSV vaccine candidates using post-
fusion protein or a nanoparticle-based vaccine candidate with
a morphology consistent to that of post-fusion failed, suggesting
the importance of pre-F-specific antigenic sites (e.g. sites Ø and
VIII) and the pre-F morphology in eliciting a protective immune
response.
● A protective immune response as therapeutic outcome and the
(storage) stability of the vaccine remain challenges in the develop-
ment of subunit-based RSV vaccines.
● The several disadvantages of vaccine candidates described in this
review may be overcome by using a dry powder pre-fusion vaccine
suitable for pulmonary administration.
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3. The viral envelope glycoproteins
This section is devoted to the viral envelope glycoproteins.
The viral envelope glycoproteins, the F protein and the
G protein, are involved in virus entry into the target cell. G is
the receptor-binding protein, while F has membrane fusion
activity. Both proteins have been shown to elicit VN antibodies
[24]. Clearly, antibodies directed to G interfere with binding of
RSV virions to cellular receptors, while antibodies directed to
F inhibit viral membrane fusion. Therefore, these glycoproteins
are promising antigens in the development of a subunit vac-
cine against RSV [39].
3.1. The F protein
As already mentioned above, the RSV F protein is crucial for
virus cell entry, mediating fusion of the viral envelope with the
host cell plasma membrane [24]. Through this fusion event, the
viral genome is deposited into the cytosol of the host cell. The
RSV F protein belongs to the so-called type I viral membrane
fusion proteins [24,40]. When the F protein is expressed at the
surface of infected cells, it can also induce the formation of
syncytia bymediating fusion between neighboring cells [24,40].
The F gene encodes an inactive precursor protein, F0. A trimer is
assembled consisting of three identical F0 monomers [24]. The
Figure 1. Structure of RSV. The nucleocapsid is a symmetrical helix and is surrounded by a lipid envelope. The surface proteins F, G, and SH protrude from the
outside of the lipid bilayer. Reproduced with permission from [29].
Figure 2. The RSV genome, proteins, and their functions. The genome contains 15,200 nucleotides, encoding 11 different proteins. Reproduced with permission
from [29].
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F0 precursor protein is activated by proteolytic cleavage at two
sites [24,41], resulting in the formation of an F1 (48 kDa) and an
F2 (23 kDa) subunit [42] and the release of the intervening p27
peptide [24,41]. The F1 and F2 subunits are covalently linked by
two disulfide bonds [24]. The first cleavage occurs in the pro-
ducer cells and generates the F2 and the F1 subunits [43]. There
are indications that the second proteolytic cleavage, resulting
in the release of p27, occurs after macropinocytosis [43]. It is
known that nucleolin on the cell surface can mediate macro-
pinocytosis [44]. Interestingly, Tayyari et al. [45] identified
nucleolin as cellular receptor for the F protein, suggesting the
involvement of nucleolin in macropinocytosis of RSV. The
release of p27 generates a hydrophobic N terminus of F1,
which is known as the fusion peptide of the mature pre-F
form of the protein [41,43]. It is the mature pre-F conformation
of the F protein that has the capacity to induce membrane
fusion by partially refolding and inserting its hydrophobic
fusion peptide into the target membrane [24,40,41]. The fusion
event is then further facilitated by a conformational change
from pre-F to post-F [41]. The trigger for the fusion event is
still unknown [24,41]. Figure 3 shows the structures of pre-F and
post-F [41].
The F proteins of the two subtypes, RSV A and RSV B, are at
least 90% identical in amino acid sequence [24]. As described
above, the F protein is located on the surface of the virus and is
essential for virus cell entry. This makes the F protein an ideal
antigen for the development of subunit-based RSV vaccines [24].
However, both the pre-F and the post-F protein have their short-
comings as antigen for an RSV vaccine. Clearly, effective VN
antibodies need to interact with the pre-F conformation of the
F protein, thus blocking fusion between the viral envelope and
the host cell membrane [46]. Accordingly, it would appear that
pre-F is the preferred conformation of F in a vaccine candidate.
However, pre-F is a metastable protein, which readily flips into
the stable post-F conformation, also in absence of membrane
interaction of the protein [46,47]. Post-Fmay be used as a vaccine
antigen because it shares antigenic epitopes with pre-F (sites II
and IV, see Figure 3) [41,47,48]. Therefore, antibodies elicited
against post-F may still be able to neutralize viral membrane
fusion activity mediated by pre-F. However, post-F lacks several
epitopes of pre-F, including the well characterized antigenic site
Ø (see Figure 3) [24,47,49], which tertiary structure changes
during the transition from pre-F to post-F [41]. Other pre-
F-specific epitopes, such as the antigenic site VIII (comprising
parts of sites II, V, and Ø) [41,50] and a quaternary pre-F-specific
epitope (positioned halfway between the membrane-proximal
region and the apex of the pre-F trimer) [41,51] have recently
been characterized. Therefore, post-F, although stable and thus
more practical to work with than pre-F, would appear to be the
less favorable antigen for the induction of fusion-inhibitory activ-
ity, and thus VN antibodies.
3.2. The G protein
The G protein is glycosylated, which is important for attach-
ment to the target cell [29]. The main receptor for the G protein
appears to be the CX3CR1 chemokine receptor [24,52],
although other cellular proteins have been implicated in recep-
tor binding of RSV as well [24]. RSV G also binds to heparin
sulfate, found on the surface of most cells [24]. The main
difference between RSV A and RSV B is the amino acid sequence
of the G proteins [28,29]. VN antibodies directed against the
G proteins of both RSV subtypes might be needed to provide
sufficient protection against RSV [28]. However, it has been
shown that the addition of the G protein to F protein-based
vaccines may enhance VN antibody titers [53–55].
4. RSV subunit vaccine candidates based on the viral
envelope glycoproteins
As of late, the scientific community is getting closer to the
development of a safe and effective subunit-based RSV vac-
cine using the viral envelope glycoproteins as antigens.
A concern in the development of an RSV vaccine, is that RSV
infections, and thus potentially also vaccination, do not induce
(long-lasting) protective immunity. In addition, since subunit-
based vaccines are composed of non-replicating component-
(s) of the virus, they are often poorly immunogenic [56,57].
Another concern is the quality of the immune response. For
optimal protection, a balanced Th1/Th2 response is desired for
the induction of immunological memory, cellular immunity,
Figure 3. Structures of pre-F (upper) and post-F (lower). The left panels show
the structures of pre-F and post-F with one monomer depicted as a ribbon. The
right panels show the structures of pre-F and post-F with three monomers. The
antigenic sites are indicated with color (red: site Ø, blue: site I, yellow: site II,
green: site III, magenta: site IV, and orange: site V). Reproduced with permission
from [41].
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and potent VN antibodies [58]. To meet these requirements,
subunit-based vaccines may require adjuvants and/or multiple
administrations to boost the immune response [56–58]. Other
ways to boost the immune response and to regulate the Th1/
Th2 response include the formulation of virus-like particles
(VLPs), nanoparticles, and virosomes. The focus of this review
is on subunit-based RSV vaccines using the viral envelope
glycoproteins, in particular the F protein, as antigens. These
candidates include vaccines based on soluble viral envelope
glycoprotein, VLPs, nanoparticles, and virosomes.
4.1. Soluble viral envelope glycoprotein vaccines
Recently, protein engineering has gained considerable interest
as a tool to develop effective subunit-based vaccines [59]. By
using this technique, tailor-made subunit-based vaccines may
be produced and the stability and/or immunogenicity of the
vaccine may be improved. Another way to increase the immu-
nogenicity and control the Th1/Th2 response of subunit-based
vaccines is the use of adjuvants. However, only a few adju-
vants are licensed for human use [56]. Therefore, novel adju-
vants have recently been developed and evaluated in
combination with subunit-based vaccines. This section reviews
strategies applied to develop safe and efficient soluble viral
envelope glycoprotein vaccines. Vaccine candidates tested in
preclinical studies are first discussed, followed by an overview
of candidates tested in clinical studies. Table 1 gives an over-
view of the in vivo studies discussed in this review that used
soluble viral envelope glycoprotein, in particular the F protein,
as vaccine candidates.
4.1.1. Vaccine candidates in preclinical development
McLellan et al. [49] designed a soluble pre-F antigen called DS-
Cav1. It was attempted to stabilize this antigen in the trimeric
pre-F conformation by introducing disulfide bonds (DS), filling
hydrophobic cavities with hydrophobic substitutions (Cav1), and
retaining the C-terminal trimerization domain. A two-dose intra-
muscular immunization of CB6F1/J mice and rhesus macaques
with DS-Cav1 adjuvanted with poly I:C (synthetic double-stranded
RNA) resulted in high titers of VN antibodies, directed against the
antigenic site Ø of the pre-F protein. These VN antibodies are also
known as D25-competing antibodies, as D25 is a monoclonal
antibody binding to antigenic site Ø. These high titers make DS-
Cav1 a promising candidate for an effective RSV vaccine. However,
it has been shown that DS-Cav1 (in an aqueous solution) is not
stable during prolonged storage (102 days) at 4°C [60]. The con-
formation of DS-Cav1 changed to one that was distinct from the
pre-F and the post-F conformation of the protein [60]. In the
changed conformation, the specific antigenic site Ø was lost,
which is an important target for VN antibodies as argued above.
Therefore, an improved version of DS-Cav1 was designed, which
resulted in the second generation DS-Cav1, named DS2 [61]. In
DS2, the F subunits (F1 and F2) were genetically linked, the fusion
peptides were deleted, and an additional disulfide bond was
introduced, reducing the movement between the monomers.
According to the authors, a major advantage of DS2 is its
improved antigenic stability against heat inactivation (for 60 min
at 60°C). In addition, DS2 adjuvanted with poly I:C induced an
approximately four-fold higher VN activity than DS-Cav1 in
RSV-naïve CB6F1/J mice after two intramuscular immunizations.
However, the (long-term) storage stability of DS2 was not inves-
tigated. The performed experiments only showed an increased
antigenic stability upon heat shock. Moreover, no challenge study
was performed. Therefore, further research is needed to demon-
strate whether DS2 is suitable as a vaccine antigen.
In 2018, Zhang et al. [62] performed additional structure-
based design on DS-Cav1 to improve its stability, leading to
a properly folded candidate named F111. To produce F111,
the furin cleavage sites, the p27 peptide, and part of the
fusion peptide were replaced with a twelve amino acid flexible
linker. In addition, an inter-trimer disulfide mutation was intro-
duced. Compared to DS-Cav1, F111 showed an improved heat
stability and an improved prolonged storage stability at 4°C
(no increased 4D7 (post-F-specific antibody) binding up to
three months). However, it is not clear whether D25 binding
(antigenic site Ø) remains stable over this period. A two-dose
intramuscular immunization of BALB/c mice with F111 adju-
vanted with aluminum showed no compromise in immuno-
genicity compared to DS-Cav1.
Krarup et al. [63] designed a highly stable pre-F vaccine
candidate, named SC-DM, from structural analysis of the
fusion mechanism. SC-DM is a single-chain (SC), with a short
linker between F1 and F2 subunits, double mutant (DM) with
an optimized apex. Using differential scanning fluorometry,
SC-DM showed refolding from pre-F to post-F at 52°C. In
addition, heated SC-DM was unable to bind to CR9501,
a pre-F-specific antibody. However, it was shown that SC-DM
remained in its pre-F conformation for at least 50 days at 4°C,
in contrast to DS-Cav1. A two-dose intramuscular immuniza-
tion of BALB/c mice with SC-DM (with or without poly I:C as
adjuvant) resulted in significantly higher neutralizing titers
than a two-dose intramuscular immunization with post-F.
Moreover, immunization with adjuvanted SC-DM resulted in
10-fold higher VN titers than immunization with adjuvanted
post-F. Subsequently, a challenge study was performed in
cotton rats with this vaccine candidate. Cotton rats were
immunized intramuscularly twice with SC-DM (with or without
AdjuPhos, an aluminum phosphate gel, as adjuvant) or twice
with post-F (with or without AdjuPhos as adjuvant). The results
were comparable to the results obtained in mice and showed
a significant enhancing effect of AdjuPhos regarding VN titers
elicited by SC-DM. Cotton rats immunized with 5 μg adju-
vanted SC-DM were completely protected from RSV challenge.
The ‘head-only’ antigen designed by Boyington et al. [64] is
based on the DS-Cav1 antigen. These authors hypothesized
that the head region of the F protein, i.e. the membrane-distal
half with an intact antigenic site Ø (see Figure 3), might elicit
a better antibody response directed against the antigenic site
Ø than the complete F protein. Therefore, the membrane-
proximal half (stalk region) of the protein was removed and
monomers, dimers, and trimers of the truncated protein were
generated. Four of the ‘head-only’ antigens adjuvanted with
poly I:C were studied in CB6F1/J mice. The ‘head-only’ antigen
i-447, a trimeric antigen, showed the most promising results.
Following two intramuscular administrations to mice, i-447
elicited VN titers comparable to those induced by DS-Cav1.
However, higher levels of antibodies directed against anti-
genic site Ø were found than with DS-Cav1. Compared to
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DS-Cav1, i-447 showed an increased thermostability (no loss of
site Ø antigenicity when heated for 60 min at 70°C), although
a heat shock for 60 min at 90°C resulted in a substantial loss of
site Ø antigenicity (only 10% remaining). Unfortunately, the
stability of i-447 upon (prolonged) storage was not investi-
gated. Moreover, a challenge study was not conducted.
Garg et al. [65] showed that a ΔF/TriAdj-vaccine protected
rodents for at least one year from RSV infection. The ΔF/TriAdj-
vaccine consists of a truncated shortened form of the native
F protein (ΔF). To produce ΔF, the transmembrane domain of
the protein was deleted. The ΔF protein was formulated with
three different adjuvants, namely poly I:C, an immune defense
regulator peptide (IDR1002), and a polyphosphazene (poly[di
(sodium carboxylate ethyl phenoxy)phosphazene] (PCEP)).
Intranasal immunization of BALB/c mice with this vaccine candi-
date induced higher mucosal IgA production than did two intra-
nasally administered doses of live RSV A2 strain. It also induced
higher numbers of B-, Th-, and antibody-secreting plasma cells
(in the lymph nodes), and elicited increased expression of inter-
leukin (IL)-6, IL-21, and transforming growth factor-β, resulting in
longer lasting immunogenic protection than that induced by
infection with live RSV [66]. In 2017, Garg et al. [67] showed
that a single dose of intranasally administered ΔF/TriAdj-
vaccine also resulted in a long-term protective immunity. BALB/
c mice challenged 25 weeks post-immunization showed com-
plete protection against RSV. In another study, ΔF/TriAdj was
evaluated as a maternal vaccine [68]. By vaccinating pregnant
ewes twice, it was shown that thematernal antibodies (IgG) were
transferred to the lambs. The lambs were challenged intranasally
with RSV and had lower virus replication and lung pathology
than control animals. This indicates that maternal immunization
with ΔF/TriAdj might be safe and effective.
Passmore et al. [69] used an intranasally administered
recombinant F protein (rF-ptn) adjuvanted with a nanoemul-
sion. Unfortunately, the conformation of the F protein was not
described. The nanoemulsion consisted of Tween 80 (5%),
ethanol (8%), cetyl pyridinium chloride (1%), soybean oil
(64%), and water. This oil-in-water system with a droplet size
of approximately 500 nm was mixed with rF-ptn to obtain the
final formulation. The formulation was administered twice,
intranasally, to BALB/c mice and gave good humoral (IgG
and IgA) responses. High neutralization activity was found
and an enhanced viral clearance after RSV challenge was
seen. However, as mice were challenged two weeks after
administration of the second dose of the vaccine, the duration
of the immune response remained unclear.
Cherukuri et al. [70] investigated the effect of the adjuvant
Al(OH)3 by intramuscularly vaccinating young (8 weeks) and
aged (18 months) BALB/c mice twice with the F protein (con-
formation not described), with or without the Al(OH)3 adju-
vant. After challenge, it appeared that the vaccine with
Al(OH)3 protected both young and aged mice to a higher
degree than the vaccine without adjuvant. Also, the vaccine
with Al(OH)3 induced higher VN antibody titers in young mice
(completely protected) than in aged mice. Therefore, a higher
antigen dose and/or adjuvant might be needed for the elderly.
The duration of the immune response was not investigated, as
mice were challenged already two weeks after receiving
the second dose of the vaccine.
In 2018, Khan et al. [71] produced FG-Gb1, a recombinant
protein meant for intranasal vaccination. FG-Gb1 was pro-
duced by genetically fusing the core fragments of the F and
the G proteins with Gb-1 (a microfold cell-specific ligand) by
using a flexible linker. The authors hypothesized that by using
Gb-1, the antigen is targeted to differentiated microfold cells
of the nasopharynx-associated lymphoid tissue (NALT), leading
to an efficient antigen delivery to the underlying immune
induction site. To investigate this, BALB/c mice were intrana-
sally immunized twice with either FG-Gb1 or FG (the frag-
ments without Gb1). Mice that were immunized with FG-Gb1
showed significant increases in antigen-specific serum IgG,
IgG-secreting cells in the splenocytes, antigen-specific IgA-
secreting cells, sIgA in NALT, and VN antibody titers compared
to mice immunized with FG. In addition, mice immunized with
FG-Gb1 were protected from RSV challenge. Unfortunately, the
stability of the formulation and the duration of the immune
response were not investigated.
4.1.2. Vaccine candidates in clinical development
In a phase I study, an RSV vaccine ultimately intended for
pregnant women was tested with purified recombinant
F protein in the pre-F conformation [72]. It was unclear how
the antigen was stabilized in its pre-F conformation. The
safety, reactogenicity, and immunogenicity were evaluated.
In addition, the use of the adjuvant Al(OH)3 was investigated.
In the trial, 128 healthy men, 18–44 years old (of whom 121
completed the study), received an intramuscular injection of
the vaccine, containing 10, 30, or 60 µg of pre-F protein, with
or without 500 µg Al(OH)3. The vaccine elicited a rapid VN
antibody (IgG) response (7 days after vaccination) and had an
acceptable adverse events profile. The most commonly
reported adverse events were temporary pain at the injection
site and mild fatigue. The highest antibody titers were found
in the groups that received 30 µg pre-F protein/Al(OH)3, 60 µg
pre-F protein/Al(OH)3, or 60 µg pre-F protein without adju-
vant. The antibody titers decreased at day 60 and decreased
even further at day 180 and day 360. However, VN antibody
titers for these three groups at day 360 were still higher than
baseline. Unfortunately, no conclusions about the effects of
the adjuvant Al(OH)3 could be drawn due to the relatively
small sample size. In 2017, a planned phase II study aimed to
evaluate the safety, reactogenicity, and immunogenicity of
this vaccine in healthy pregnant women and postpartum in
their infants was canceled due to instability of the pre-F anti-
gen during manufacturing [73].
Another phase Ia study was conducted with a vaccine con-
taining soluble fusion protein (sF) in adults over 60 years of age
[74]. The post-F conformation of the F protein was used.
Because the cell-mediated immune system of the target
group (the elderly) is in general not easily stimulated, the addi-
tion of an adjuvant was applied to boost cellular and humoral
immune responses. The synthetic analog of monophosphoryl
lipid A, glucopyranosyl lipid A (GLA), was used as an adjuvant,
which is a toll-like receptor 4 (TLR4) agonist. GLA was formu-
lated in a 2% squalene-based oil-in-water emulsion (SE). In this
study, subjects received the sF vaccine containing 20, 50, or
80 μg post-F protein with or without the adjuvant (2.5 μg of
GLA in 2% SE) intramuscularly. The results of the study were
EXPERT REVIEW OF VACCINES 941
promising, as the safety profile was acceptable for all doses
studied and the adjuvant GLA-SE stimulated both humoral and
cellular immune responses (micro-neutralization, RSV-specific
IgG, and IFN-γ). The immune responses were dose-dependent
and did not reach a plateau. Therefore, the efficacy of the
vaccine was examined in a larger clinical Ib trial [75]. Subjects
of ≥ 60 years received 120 μg sF with different doses of GLA-SE
(1, 2.5, or 5 μg), or 80 μg sF with 2.5 μg GLA-SE. The main
objectives of the study were to investigate the tolerability and
safety of the formulations, and to gather immunogenicity data
for dose selection for a subsequent phase II study. The results of
the phase Ib study showed that a higher GLA-SE dose augmen-
ted local tenderness and pain. However, even for the formula-
tion with the highest dose of GLA-SE, the safety profile
remained acceptable. The highest immunogenic response was
seen for the formulation containing 120 μg sF adjuvanted with
5 μg GLA-SE. Therefore, this formulation was selected for phase
II evaluation. In 2017, the results of this phase II study per-
formed in 1,900 participants of ≥60 years showed that the
vaccine was immunogenic, but did not protect from RSV illness
[76]. A possible explanation for this outcome, given by the
authors, was that the vaccine in the post-F conformation was
not able to appropriately generate VN antibodies to prevent
RSV illness due to the absence of antigenic site Ø.
In 2017, a phase I study was started with DS-Cav1, despite
the fact that this RSV vaccine candidate underwent
a conformational change upon long-term storage (102 days)
at 4°C. The results of this study are expected to be published
soon [77].
4.2. Particulate subunit vaccines
While, in the previous section, we discussed RSV subunit vaccine
candidates based on soluble envelope glycoprotein antigens,
this section reviews strategies to develop safe and efficient sub-
unit vaccines based on the use of particulate formulations.
Particulate vaccine formulations in general offer specific advan-
tages over soluble protein vaccines, including multimeric anti-
gen presentation and improved uptake and processing by
antigen-presenting cells [78]. A further distinction within this
category is made between vaccine candidates based on virus-
like particles (VLPs), nanoparticles, and virosomes.
4.2.1. Virus-like particles (VLPs)
VLPs are supra-molecular complexes, resembling the structure
of native viruses. VLPs are generally produced through expres-
sion of one or more viral structural proteins, such as surface
glycoproteins derived from enveloped viruses, in prokaryotic
or eukaryotic expression systems, and often contain a lipid
envelope derived from the production cell system [79,80].
Several expression systems for generation of VLPs have been
described, including E. coli, yeast, insect, or even plant cells
[79,80]. A major advantage of VLPs is that they are known to
induce potent B- and T-cell responses [81,82]. Using eukaryotic
expression systems, VLPs containing RSV envelope glycopro-
teins have also been produced. This section is devoted to RSV
vaccine candidates based on the use of VLPs containing the
viral envelope glycoproteins, in particular the F protein.
Table 2 gives an overview of the in vivo studies discussed in
this review that used VLPs containing the viral envelope gly-
coproteins, in particular the F protein, as vaccine candidates.
Lee et al. [83] investigated whether immunization with
a combination of VLPs containing the F protein and VLPs
containing the G protein (VLP F + VLP G) leads to an enhanced
vaccination efficacy compared to VLPs containing the
F protein (VLP F) or VLPs containing the G protein (VLP G)
alone. To investigate this, BALB/c mice were vaccinated intra-
muscularly twice with either VLP F, VLP G, or VLP F + VLP G. All
vaccine candidates were in complex with influenza M1, the
conformation of the F protein was not investigated. It was
shown that mice vaccinated with VLP F + VLP G had lower
lung viral loads after RSV challenge, possibly due to an
increased CD8 T cell cytokine expression. However, VN anti-
body titers of mice vaccinated with VLP F alone were similar to
mice vaccinated with VLP F + VLP G. Moreover, vaccination
with VLP G resulted in an enhanced immunopathology. The
duration of the immune response was not investigated, as the
challenge experiment was performed three weeks after
administration of the second dose of the vaccine.
Table 2. An overview of the in vivo studies discussed in this review that used VLPs containing the viral envelope glycoproteins, in particular the F protein, as vaccine
candidates (study period: 2012–2018).
Vaccine candidate
Route of
administration Dose vaccine Adjuvant Species Immune response Reference
VLP F, VLP G, or VLP
F + VLP G
IM 25 μg
(12.5 μg + 12.5 μg
for VLP F + VLP G)
N/A BALB/c
mice
VLP F + VLP G showed lower lung viral loads and





IN 40 μg (20 μg + 20 μg
for rNDV/RSV/F + G)
N/A BALB/c
mice
rNDV/RSV/F + G showed highest serum IgG, highest
nasal serum IgA,









Complete protection for all candidates, combo VLP






IM 30 µg N/A BALB/c
mice
High VN antibody titers for VLP-H/G+ pre-F/F, low VN





IM 100 µg N/A Cotton
rats
VLP-H/G+ pre-F/F most efficient in boosting VN
antibodies in mothers, pups showed enhanced VN
antibody titers and protection of the lung from RSV
replication after challenge
[87]
IFN-γ: Interferon-γ; IL-4: Interleukin-4; IM: Intramuscular; IN; Intranasal; N/A: Not applicable. ± indicates with or without adjuvant.
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In a comparable study, Newcastle disease virus (NDV) was
used as platform for VLPs containing the RSV F protein (rNDV/
RSV/F) and/or G protein (rNDV/RSV/G) [84]. In this study, mice
were intranasally vaccinated twice with either rNDV/RSV/F,
rNDV/RSV/G, or a combination of both (rNDV/RSV/F + G).
Mice that were vaccinated with rNDV/RSV/F + G showed the
highest serum IgG titers, the highest nasal serum IgA titers,
and highest levels of IFN-γ and IL-4. Moreover, mice vacci-
nated with rNDV/RSV/F + G showed better protection after
RSV challenge than mice vaccinated with rNDV/RSV/F or rNDV/
RSV/G alone. Unfortunately, the conformation of the F protein
was not described. In addition, it is not clear when the chal-
lenge experiments were performed.
Cimica et al. [85] used the M protein of human metapneu-
movirus as scaffold together with recombinant post-F, pre-F,
or a combination of both for their VLPs. The pre-F protein was
stabilized by introducing two disulfide bonds. A squalene-
based oil-in-water emulsion was used as adjuvant. Two intra-
muscular administrations with the vaccine containing both
post-F and pre-F protein yielded complete protection against
RSV challenge and no viral lung replication in challenged
BALB/c mice was seen. Furthermore, this formulation showed
a balanced Th1/Th2 response and gave the highest VN anti-
body titers, followed by the pre-F only formulation. The post-F
protein VLP vaccine gave the lowest neutralizing antibody
titers. Unfortunately, the (prolonged) stability of the formula-
tion was not tested. Moreover, the duration of the immune
response was not investigated, as the challenge experiment
was performed already two weeks after administration of
the second dose of the vaccine.
Cullen et al. [86] investigated whether previously RSV-
infected mice generated protective immune responses when
vaccinated with their VLPs. This study was performed to inves-
tigate the effect of pre-existing immunity on vaccination effi-
cacy, which is important for vaccine candidates meant for
pregnant women and the elderly. The authors used NDV
core proteins to develop VLPs containing chimera H/G protein
and either chimera pre-F/F (VLP-H/G+ pre-F/F) or chimera
post-F/F (VLP-H/G+ post-F/F), to investigate the influence of
the conformation of the F protein on the immune response.
Mice were first infected with RSV by intranasal inoculation.
Then, 95 days post-infection, mice were immunized intramus-
cularly with either VLP-H/G+ pre-F/F or VLP-H/G+ post-F/F.
After vaccination, high VN antibody titers were observed in
mice that were immunized with VLP-H/G+ pre-F/F, in contrast
to mice that were immunized with VLP-H/G+ post-F/F. These
results indicate that VLPs containing the F protein in its pre-F
conformation are able to induce a VN antibody memory
response, in contrast to VLPs containing the post-F conforma-
tion. Therefore, the conformation of the F protein seems to be
of great importance in vaccine candidates intended for preg-
nant women and the elderly.
In 2018, the efficacy of VLP-H/G+ pre-F/F and VLP-H/G +
post-F/F was assessed in a maternal immunization model
using cotton rats [87]. A subgroup of female cotton rats was
intranasally infected with RSV. Subsequently, all female cotton
rats were set up in breeding pairs at week 8. At week 10,
pregnant cotton rats were intramuscularly vaccinated with
VLP-H/G+ pre-F/F, VLP-H/G+ post-F/F, purified pre-F, or
purified post-F. At 12 weeks, cotton rats delivered their pups,
which were intranasally challenged with RSV at 4 weeks of
age. The results of this study were comparable to the results of
the previous study and showed that VLPs containing pre-F
were more efficient in boosting pre-existing VN antibodies
than VLPs containing post-F. In addition, VLPs containing
pre-F were also more efficient than purified F protein (pre-F
as well as post-F). Pups born to mothers that were immunized
with VLP-H/G+ pre-F/F showed enhanced VN antibody titers
and protection of the lung from RSV replication after chal-
lenge. Unfortunately, the (prolonged) stability of the formula-
tion was not tested.
4.2.2. Nanoparticles
In recent years, the use of nanotechnology in vaccine devel-
opment increased significantly. Nanoparticles are more simple
structures than VLPs, usually lacking a lipid envelope and
consisting of a self-assembled oligomeric viral protein, such
as – for example – RSV F. The main advantages of nanoparti-
cle-based vaccines are an increased antigen stability and an
enhanced immunogenicity [88,89]. Table 3 gives an overview
of the in vivo studies discussed in this review that used nano-
particles containing the viral envelope glycoproteins, in parti-
cular the F protein, as vaccine candidates.
A recombinant F protein nanoparticle vaccine was devel-
oped by Smith et al. [90]. This vaccine contained a modified
almost full length F protein produced in Spodoptera frugiperda
insect cells infected with a recombinant baculovirus. The
nanoparticles (approximately 40 nm in size) were composed
of F protein oligomers arranged in the form of rosettes with-
out a lipid envelope. The F protein oligomers had a morphol-
ogy consistent with the post-F conformation. Different doses
(1, 6, or 30 µg) with or without 120 μg AlPO4 as adjuvant were
tested. All doses protected cotton rats from RSV challenge
after a two-dose intramuscular immunization. High serum
IgG levels and neutralizing activity were found for the animals
vaccinated with the F protein nanoparticles, the highest titers
were found with the adjuvanted vaccine candidate.
Immunization of cotton rats with the vaccine containing
AlPO4 elicited serum levels of palivizumab-competing antibo-
dies greater than after passive administration of palivizumab
[91]. Therefore, the vaccine is potentially more broadly protec-
tive than palivizumab. Unfortunately, no (prolonged) stability
data were available and the duration of the immune response
is not clear, as the animals were challenged 4 weeks after
receiving the second dose of the vaccine.
Recombinant F protein nanoparticle vaccines based on the
vaccine developed by Smith et al. [90] described above, are
under clinical evaluation. The vaccines are meant for pregnant
women in their third trimester, the elderly, and children with
an age between 6 months and 5 years. In a phase III study
with 11,850 participants (≥60 years), the nanoparticle vaccine
meant for the elderly failed to show efficacy against RSV
moderate-severe lower respiratory tract disease [92–94].
As a phase III study for the vaccine meant for pregnant
women is still ongoing, this vaccine will be discussed in more
detail. The nanoparticle vaccine for pregnant women was first
tested in pregnant guinea pigs [95] and two clinical trials in
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healthy women of childbearing age were subsequently per-
formed. The pregnant guinea pigs were immunized twice with
30 μg F protein with or without 400 μg AlPO4. Both the non-
adjuvanted and adjuvanted vaccine yielded high IgG titers,
palivizumab-competing antibodies, and serum showed RSV
neutralizing activity in vitro. However, the adjuvanted vaccine
gave a more potent immune response. The results showed
adequate antibody transfer to the pups for both the adju-
vanted and the non-adjuvanted groups. In the first phase II
clinical study, healthy non-pregnant women (18–35 years old)
were intramuscularly immunized with 1 or 2 dose(s) of the
vaccine (60 or 90 µg) with or without 1.2 mg AlPO4 as adju-
vant [96]. The vaccine appeared to be safe, immunogenic, and
reduced RSV infections. High serum IgG antibody levels were
found in all groups, which were still detectable after 112 days.
The best results were obtained when the vaccine with adju-
vant was administered twice. A modest increase in antibody
levels was observed for the higher antigen dose (90 μg). For
the second phase II study, non-pregnant women (18–35 years
old) were vaccinated intramuscularly with 1 or 2 dose(s) of
60 μg or 120 μg adjuvanted with 0.2, 0.4, or 0.8 mg AlPO4 [97].
All formulations were immunogenic and well tolerated. The
formulation of a single dose of 120 μg adjuvanted with 0.4 mg
AlPO4 was the formulation with an optimal combination in
terms of efficacy and convenience. The safety and immuno-
genicity of the F protein nanoparticle vaccine, with AlPO4, is
currently being studied in healthy, pregnant women in their
third trimester. In this phase III study, 4,636 third trimester
pregnant women were enrolled [98,99]. The study completion
date is estimated by July 2019. However, it was recently
reported that the study did not meet its primary objective
(prevention of medically significant RSV lower respiratory tract
infections) [99]. The efficacy of the vaccine through 90 days of
life in infants against medically significant RSV lower respira-
tory tract infections was reported to be 39.4% [100].
In 2018, Gilbert et al. [101] characterized the immune
response to the RSV F nanoparticle vaccine described above.
To this end, the authors immunized cotton rats intramuscu-
larly twice with 10 μg of the RSV F nanoparticle vaccine with
or without 60 μg aluminum phosphate as adjuvant.
Subsequently, sera were analyzed on cross-competition of
F antigenic site specific monoclonal antibodies, namely: D25
for site Ø (pre-F-specific), motavizumab for site II, NVX for site
IV, and hRSV90 for site VIII (pre-F-specific). Despite the fact
that a morphology consistent with that of the post-F confor-
mation was previously reported for this candidate [90], the
serum of cotton rats that had been immunized with the RSV
F nanoparticle vaccine cross-competed with all monoclonal
antibodies, including the pre-F-specific monoclonal antibodies
D25 and hRSV90. This was also supported by the fact that
cotton rats immunized with the RSV F nanoparticle vaccine
were protected against challenge with a palivizumab-resistant
mutant virus. These data show that multiple neutralizing epi-
topes, including the pre-F-specific sites Ø and VIII, are targeted
upon immunization with the RSV F nanoparticle vaccine.
Cotton rats immunized with the adjuvanted vaccine showed
higher anti-F IgG and micro neutralizing titers. In addition, the
adjuvant increased site II antibody avidity, which resulted in
an enhanced protection against RSV challenge.
Francica et al. [102] used TLR agonists as adjuvants to an
F protein (in the pre-F conformation (DS-Cav1)) vaccine to
enhance antibody responses in CB6F1/J mice. The authors
discovered that conjugation of F protein to TLR-7/8a disrupts
the recognition of critical VN epitopes. However, if the
Table 3. An overview of the in vivo studies discussed in this review that used nanoparticles containing the viral envelope glycoproteins, in particular the F protein, as
vaccine candidates (study period 2012–2018).
Vaccine candidate
Route of
administration Dose vaccine Adjuvant Species Immune response Reference
RSV F nanoparticles IM 1, 6, or 30 µg ±120 µg AlPO4 Cotton rats High IgG levels, neutralizing activity,
protection from challenge for all doses
[90]
RSV F nanoparticles IM 30 μg ±AlPO4 Cotton rats Adjuvanted vaccine induced higher serum
levels of palivizumab-competing antibodies
than passive administration of palivizumab
[91]
RSV F nanoparticles IM 135 μg N/A Adults (≥60 years) Vaccine did not show efficacy against RSV
moderate-severe lower respiratory tract
disease
[92–94]
RSV F nanoparticles IM 30 µg ±400 µg AlPO4 Pregnant guinea pigs High IgG titers and neutralizing activity,
adjuvant enhances immune response
[95]
RSV F nanoparticles IM 60 or 90 µg ±1.2 mg AlPO4 Healthy women
(18–35 years)
High IgG antibody levels, increased
microneutralization antibodies, best results
with 2 adjuvanted doses
[96]





Optimal formulation: one dose 120 µg
adjuvanted with 0.4 mg AlPO4
[97]
RSV F nanoparticles IM 120 μg 0.4 mg AlPO4 Third trimester pregnant
women (18–40 years)
The efficacy against RSV lower respiratory
tract infections through 90 days of life in
infants was 39.4%, trial did not meet its
primary objective
[98–100]
RSV F nanoparticles IM 10 μg ±60 μg
AdjuPhos
Cotton rats Induction of antibodies targeting multiple
neutralizing epitopes, use of adjuvant
resulted in enhanced protection against
RSV challenge
[101]
Coupled RSV F/TRP SC 3–5 µg 5.15 nmol
TLR7/8a
CB6F1/J mice High pre-F specific antibody titers mediated
by Th1, protection against RSV challenge
[102]
AdjuPhos: Aluminum phosphate gel; AlPO4: Aluminum phosphate; IM: Intramuscular; SC: Subcutaneous; TLR7/8a: Toll-like receptor7/8a. ± indicates with or without
adjuvant.
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F protein was coupled to nanoparticle-forming thermorespon-
sive diblock co-polymers (consisting of N-(2-hydroxypropyl)
methacrylamide (HPMA) and di(ethylene glycol) methyl ether
methacrylate (DEGMA)) and if TLR-7/8a was used as adjuvant,
high titers of pre-F specific antibodies mediated by Th1 cells
were obtained. This formulation seems to have appropriate
antigenicity, as the mice were fully protected from RSV chal-
lenge after being immunized subcutaneously twice. However,
the duration of the immune response is unclear, since the
mice were challenged only 17 days after vaccination.
Moreover, the (long-term) storage stability of the formulation
was not investigated.
4.2.3. Virosomes
Virosomes are VLPs, in the sense that they closely resemble
the virus they are derived from. However, unlike the VLPs
discussed above in section 5.2.1, virosomes are produced
from native virus through a detergent solubilization and sub-
sequent reconstitution procedure. Thus, virosomes are recon-
stituted viral envelopes. They lack the viral genetic material
and therefore are non-replicating. Virosomes have been ori-
ginally produced from influenza virus [103,104]. Using the
detergent octaethyleneglycol mono (n-dodecyl) ether (C12E8),
Stegmann et al. [104] demonstrated that the envelope of
influenza virions could be efficiently solubilized; after sedi-
mentation of the viral nucleocapsid through ultracentrifuga-
tion and subsequent removal of the C12E8 from the
supernatant by the addition of a hydrophobic resin, reconsti-
tuted viral envelopes were formed which retained the viral
receptor-binding and membrane fusion activities. In a follow-
up study, the virosomal production procedure was adjusted;
C12E8 was replaced by a short-chain phospholipid, dicaproyl-
phosphatidylcholine (DCPC) [105]. Unlike C12E8, DCPC is
removable by dialysis because of its high critical micelle
concentration.
Since virosomes retain the morphology and cell interaction
characteristics of the native virus, they represent excellent
non-replicating vaccine formulations. This has been demon-
strated extensively for virosomes derived from influenza virus
[106]. Not only can influenza virosomes be used as vaccine
against influenza infection, they may also be employed as
carriers of foreign antigens, for induction of both antibody
and cell-mediated immune responses, including CD8 T cell
responses [106]. An additional advantage of virosomes relates
to the opportunity to incorporate lipophilic or amphiphilic
adjuvants in the virosome membrane during the reconstitu-
tion procedure [106]. Table 4 shows an overview of the in vivo
studies discussed in this review that used RSV virosomes as
vaccine candidates.
Using the DCPC-dialysis procedure, virosomes have been
produced from RSV and evaluated for their immunogenicity in
animal model systems. Initial studies were carried out by
Stegmann et al. [107] and Kamphuis et al. [108–110], who
incorporated TLR2- or TLR4-ligands as vaccine adjuvants in
the virosomal membrane, respectively. When administered
intramuscularly to mice or cotton rats, these virosomes
induced robust VN antibody and T helper cell responses,
with a balanced Th1/Th2 signature. Also, they provided com-
plete protection from viral infection upon challenge
[107,108,110]. In addition, in mice [109,111] and cotton rats
[109], protective immunity may also be induced by intranasal
administration of adjuvanted virosomal RSV vaccines.
More recently, the incorporation of TLR4-ligands, in parti-
cular non-toxic variants of bacterial monophosphoryl lipid
A (MPLA), as adjuvants in virosomal RSV candidates has further
been investigated [112]. An important improvement to the
use of this potent adjuvant system relates to the use of the
fully synthetic MPLA-derivative 3D-PHAD®, produced by Avanti
Polar Lipids, allowing vaccine production under GMP condi-
tions. The authors of the latter study also investigated the
morphology and long-term stability of the 3D-PHAD-
containing RSV virosomes. Single particle tracking showed
that the virosomes were stable for 300 days at 4°C.
5. Conclusion
For a long time, there has been a reluctance towards the
development of an RSV vaccine due to the failure and dra-
matic outcome of a study published in 1969, in which two
young children, vaccinated with an experimental FI-RSV vac-
cine, died due to vaccine-enhanced respiratory disease after
exposure to a natural RSV infection [17]. Since this disastrous
FI-RSV vaccine trial, vaccination of very young children against
RSV has remained elusive. However, there is now a growing
interest in vaccination of pregnant women to passively protect
infants against RSV in the crucial first months of their life.
Subunit-based vaccines are explicitly considered for this pur-
pose. In addition, this type of vaccine is also considered for






vaccine Adjuvant Species Immune response Reference
RSV virosomes IM 5 µg ± P3CSK4 BALB/c mice
and cotton
rats
Robust virus-neutralizing antibody and T helper cell responses,
balanced Th1/Th2, complete protection upon challenge
[107]
RSV virosomes IM 5 µg ± MPLA BALB/c mice
and cotton
rats
Robust virus-neutralizing antibody and T helper cell responses,
balanced Th/Th2, complete protection upon challenge
[108,110]
RSV virosomes IN 5 µg ± MPLA BALB/c mice
and cotton
rats
Induction of protective immunity [109]
RSV virosomes IN 5 µg ± P3CSK4 and/
or L18-MDP
BALB/c mice Induction of protective immunity [111]
IM: Intramuscular; IN; Intranasal; L18-MDP: 6-O-stearoyl-N-Acetyl-muramyl-L-anayl-D-isoglutamine; MPLA: Monophosphoryl lipid A; P3CSK4: N-palmitoyl-
S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-(lysyl)3-lysine. ± indicates with or without adjuvant.
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vaccinating another important target population, the elderly.
This is the reason why over the last years, research has been
intensified toward development of safe and effective subunit-
based RSV vaccines. This review focused on subunit-based RSV
vaccines using the viral envelope glycoproteins, in particular
the F protein, as antigens. The F protein has proven to be an
effective antigen in both the pre-F and post-F conformation,
and subunit-based vaccine candidates using the F protein as
antigen have been shown to elicit high titers of VN antibodies.
However, as yet, no vaccine candidate has been able to elicit
robust protective immunity, as demonstrated by multiple
failed clinical trials. Three of the recently failed clinical studies
used vaccine candidates with post-F protein or with
a morphology consistent with that of the post-F conformation
[76,92–94,98–100], suggesting the importance of the pre-
F-specific antigenic sites and the pre-F morphology in eliciting
protective immunity. Although a morphology consistent with
that of the post-F conformation was reported for the nano-
particle-based vaccine candidate [90], it has been shown that
the vaccine candidate induced antibodies that competed with
pre-F-specific monoclonal antibodies [101], suggesting
unknown factors in RSV subunit vaccine development. The of
use of pre-F as antigen presents stability challenges, as
demonstrated by a recently canceled phase II study with
a vaccine candidate in the pre-F conformation [73].
Therefore, induction of protective immunity and preservation
of vaccine stability remain challenges in the development of
subunit-based RSV vaccines using the viral envelope glycopro-
teins as antigens.
6. Expert opinion
Although many of the vaccine candidates described in this
review showed promising results in animal models and some
even in human trials, apparent weaknesses are obvious and
should be addressed as well. Most studies showed that immu-
nization with the vaccine candidate resulted in high titers of
neutralizing antibodies. However, in vivo challenge experi-
ments were not always carried out. The ultimate goal of
vaccination is to elicit (long-lasting) protective immunity.
While some animal studies did include in vivo challenge
experiments, these were usually carried out already
2–5 weeks after the (booster) immunization. This is rather
a short period of time, since it is well known that humoral
immunity against RSV decreases over time [72,113]. By con-
trast, there are some studies that have investigated the induc-
tion of long-term memory in animals [65–67]. These studies
showed that it was possible to induce long-term memory with
a subunit RSV vaccine based on the F protein. However, that
eliciting a protective immune response is far from trivial is also
indicated by the failure of a phase II [76] and two phase III [92–
94,98–100] studies. For these trials, the post-F protein or
a nanoparticle-based vaccine candidate with a morphology
consistent with that of the post-F conformation was used,
respectively. The post-F conformation, as previously discussed,
lacks important pre-F-specific antigenic sites, such as antigenic
sites Ø and VIII [47,49,50]. The absence of these important
epitopes may be the reason why the phase II trial failed.
However, with the nanoparticle-based vaccine candidate,
which had a morphology consistent with that of post-F [90],
antibodies competing with pre-F-specific monoclonal antibo-
dies were induced [101]. These results suggest unknown fac-
tors in RSV subunit vaccine development.
A vaccine candidate based on pre-F might be more immu-
nogenic. However, using pre-F as antigen presents its own
challenges. In 2017, a phase II study with a vaccine containing
pre-F was canceled due to instability of the pre-F antigen
during manufacturing [73]. This illustrates the major concern
regarding the use of pre-F as antigen. Modified vaccines based
on the pre-F antigen were developed. However, except for
two formulations (DS-Cav1 and SC-DM), no data are available
on the storage stability of these vaccine candidates. It should
furthermore be noticed that all formulations described in this
review are liquid (aqueous) formulations, with concomitant
disadvantages, such as a poor (storage) stability. To prevent
deterioration, liquid formulations require strictly monitored
refrigeration during storage and transport, known as the ‘cold-
chain’, which implicates logistic challenges. To overcome the
disadvantages related to liquid formulations, the development
of a dry powder vaccine may be an elegant solution [114–116].
However, an important consideration to take into account is
that the drying process itself may be detrimental to the anti-
gen, i.e. it may result in conformational changes and/or loss of
activity [114]. Excipients can be used to prevent this. Certain
sugars (e.g. trehalose, sucrose, or inulin) are known to stabilize
proteins during drying and subsequent storage and are there-
fore interesting excipients to be used for the development of
such dry powder vaccines [116,117]. Although to our knowl-
edge, pre-F has never been stabilized by drying, several other
subunit vaccines have been processed into a stable dry pow-
der, e.g. influenza haemagglutinin [118] and hepatitis
B surface antigen [119].
A dry powder RSV vaccine based on pre-F would not only
show improved (storage) stability, it might also increase the
efficacy of intranasal administration of the vaccine.
A disadvantage of liquid intranasal vaccine formulations is
their generally poor absorption over the nasal mucosa, limit-
ing their efficacy. This problem can be overcome by incorpor-
ating mucoadhesive excipients, such as chitosan, in a dry
powder vaccine formulation [120]. This will improve the
absorption of the vaccine over the nasal mucosa and therefore
increase the efficacy of the vaccine formulation, but may also
have adverse effects, including ciliotoxicity, that should be
considered when alternative formulations are developed.
A major advantage of a dry powder RSV vaccine based on
pre-F would be the possibility of pulmonary administration.
This route of administration is interesting because pulmonary
vaccination against other airborne diseases (influenza and
measles) has been proven successful in humans in several
studies [121–126]. Furthermore, the lung is the site where RSV-
related pneumonia takes place [127]. The pulmonary adminis-
tration route for vaccines has the potential to elicit both
a systemic (IgG) and mucosal (IgA) immune response
[114,115]. It is known that RSV-specific IgA has a protective
role against RSV infection [128]. This could lead to an enhanced
(longer-lasting and stronger) immune response [115]. Indeed,
Amorij et al. [129], using an influenza subunit vaccine, have
demonstrated that the pulmonary administration route has
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the capacity to elicit robust systemic humoral (IgG), mucosal
humoral (IgG and IgA), and cell-mediated immune responses in
BALB/c mice. Pulmonary administered dry powder measles
vaccine formulations have also been successfully used in cotton
rats [130] and rhesus macaques [131]. A pulmonary adminis-
tered dry powder vaccine has several advantages over
a pulmonary administered liquid vaccine, as described by
Tonnis et al. [132]. However, for such a pulmonary vaccine to
be successful, a combination between a suitable delivery device
and an optimal vaccine formulation is required [132]. For preg-
nant women and for the elderly, a dry powder vaccine could be
administered by using a disposable (single-dose) inhaler such
as the Twincer®. The ability of this inhaler to accurately deliver
drugs and its ease in use have been documented [133]. In
conclusion, the development of a dry powder subunit-based
RSV vaccine formulation using pre-F for pulmonary administra-
tion may overcome the disadvantages presented by most vac-
cine candidates discussed in this review.
In the near future, the development of subunit-based RSV
vaccines using the viral envelope glycoproteins, in particular
the F protein, as antigens will remain an interesting approach
in the development of effective RSV vaccines. The failure of
three recent clinical trials will shift research into the direction
of antigens in the pre-F conformation and with a morphology
consistent with that of pre-F, since this form has important
pre-F-specific antigenic sites, including antigenic sites Ø and
VIII. In view of the poor stability of this conformation, innova-
tive stabilization technologies are needed and they will be
essential in developing vaccine concepts that are suitable for
widespread use. Finally, research toward the development of
dry powder subunit-based RSV vaccines, based on stabilized
pre-F, will be worthwhile. Pulmonary administration of such
dry powder RSV vaccines should be explored as it may yield
clinically relevant results.
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